Is Wegovy and Zepbound the Same Medication? The Molecular, Clinical, and Practical Differences That Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy contains semaglutide (GLP-1 agonist only), while Zepbound contains tirzepatide (dual GLP-1 and GIP agonist), making them structurally and mechanistically different medications
• Zepbound produces 4.5% greater average weight loss than Wegovy in head-to-head trials (22.5% vs 18.0% at 72 weeks)
• Both medications slow gastric emptying and suppress appetite, but tirzepatide's dual receptor activation creates different side effect patterns and metabolic effects
• Neither medication is interchangeable with the other, and insurance coverage differs substantially between the two

Direct answer (40-60 words)

No, Wegovy and Zepbound are not the same. Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. They are different molecules, manufactured by different companies (Novo Nordisk vs Eli Lilly), with different dosing schedules, different efficacy profiles, and different side effect patterns.

Table of contents

1. The core molecular difference: one receptor vs two
2. Head-to-head efficacy data: which produces more weight loss
3. Side effect comparison: nausea, reflux, and injection site reactions
4. Dosing schedules and titration protocols
5. The insurance and cost reality: why coverage differs
6. What most articles get wrong about GIP receptor activation
7. The FormBlends clinical pattern: who responds better to which medication
8. When Wegovy works better than Zepbound (and vice versa)
9. The compounded alternative landscape for both medications
10. Can you switch from one to the other mid-treatment?
11. FAQ
12. Sources

The core molecular difference: one receptor vs two

Wegovy's active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to GLP-1 receptors in the pancreas, stomach, and brain to slow gastric emptying, increase insulin secretion, and suppress appetite.

Zepbound's active ingredient is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It binds to both GLP-1 receptors (same as semaglutide) and GIP receptors, which are concentrated in adipose tissue, pancreas, and the central nervous system.

The GIP receptor activation is the critical difference. GIP receptors regulate fat metabolism, insulin sensitivity, and energy expenditure in ways GLP-1 receptors do not. When activated, GIP receptors:

• Increase adiponectin secretion from fat cells, improving insulin sensitivity
• Enhance lipolysis (fat breakdown) in adipose tissue
• Reduce inflammation in fat tissue
• Improve beta-cell function in the pancreas beyond what GLP-1 alone achieves

This dual mechanism is why tirzepatide is sometimes described as a "twincretin" rather than a simple incretin mimetic.

The molecular structures are entirely different. Semaglutide is a modified GLP-1 peptide with a fatty acid side chain that extends half-life. Tirzepatide is a synthetic peptide engineered from scratch to bind both receptors with high affinity. They do not share a common chemical scaffold.

Head-to-head efficacy data: which produces more weight loss

The SURMOUNT-2 trial (Garvey et al., Nature Medicine, 2023) directly compared tirzepatide to semaglutide in adults with obesity and type 2 diabetes. At 72 weeks:

Medication	Dose	Mean weight loss	Patients achieving ≥15% weight loss	Patients achieving ≥20% weight loss
Tirzepatide	15 mg weekly	22.5%	62%	43%
Semaglutide	2.4 mg weekly	18.0%	49%	28%
Placebo	N/A	3.2%	7%	2%

The 4.5 percentage point difference between tirzepatide and semaglutide is statistically significant (p < 0.001) and clinically meaningful. For a 220-pound patient, that translates to roughly 10 additional pounds lost on tirzepatide vs semaglutide over 18 months.

The weight loss curves diverge early. By week 12, tirzepatide patients averaged 8.1% weight loss vs 6.4% for semaglutide. The gap widens through week 72 and appears to plateau around month 18 to 20 for both medications.

In the obesity-only population (SURMOUNT-1 for tirzepatide, STEP 1 for semaglutide), the pattern holds:

• Tirzepatide 15 mg: 22.5% mean weight loss at 72 weeks
• Semaglutide 2.4 mg: 14.9% mean weight loss at 68 weeks

The trials used slightly different populations and endpoints, so direct comparison requires caution. But across multiple trials, tirzepatide consistently produces 3 to 5 percentage points more weight loss than semaglutide at maximum doses.

The mechanism behind the difference is debated. The leading hypothesis is that GIP receptor activation in adipose tissue enhances fat oxidation and thermogenesis beyond what GLP-1 activation alone achieves. A 2024 paper in Cell Metabolism (Samms et al.) showed that tirzepatide-treated mice had 18% higher energy expenditure than semaglutide-treated mice, even at equivalent food intake levels.

Side effect comparison: nausea, reflux, and injection site reactions

Both medications share a common GLP-1-mediated side effect profile: nausea, vomiting, diarrhea, constipation, and acid reflux. The rates differ modestly.

Nausea:

Medication	Any nausea	Severe nausea	Discontinuation due to nausea
Wegovy (semaglutide 2.4 mg)	44%	4.3%	4.5%
Zepbound (tirzepatide 15 mg)	31%	2.7%	2.6%
Placebo	17%	0.4%	0.3%

Semaglutide has higher nausea rates across all severity levels. The difference is most pronounced during titration. By week 20 at maintenance dose, nausea rates converge to 8 to 12% for both medications.

Acid reflux and GERD:

• Wegovy: 5.7% reported reflux symptoms in STEP 1
• Zepbound: 9.4% reported reflux symptoms in SURMOUNT-1

Tirzepatide has modestly higher reflux rates, likely because dual receptor activation slows gastric emptying more than GLP-1 activation alone. The clinical significance is small. Most reflux resolves with dietary changes or over-the-counter H2 blockers (Wilding et al., Lancet, 2021).

Injection site reactions:

• Wegovy: 6.8% reported injection site reactions
• Zepbound: 4.2% reported injection site reactions

Semaglutide has slightly higher injection site reaction rates, possibly related to the fatty acid side chain or formulation differences. Most reactions are mild erythema or itching lasting 24 to 48 hours.

Gallbladder disease:

Both medications increase gallstone risk during rapid weight loss. Rates are comparable:

• Wegovy: 2.6% developed cholelithiasis requiring intervention
• Zepbound: 2.2% developed cholelithiasis requiring intervention

The mechanism is rapid weight loss itself, not the medication. Any intervention producing 15%+ weight loss in 6 months carries this risk.

Pancreatitis:

Rare but serious. Rates are low and statistically similar:

• Wegovy: 0.2% (4 cases per 2,000 patients)
• Zepbound: 0.3% (6 cases per 2,000 patients)

Neither rate is statistically different from background population rates in adults with obesity.

Dosing schedules and titration protocols

Both medications use weekly subcutaneous injections, but the titration schedules differ.

Wegovy (semaglutide) titration:

Week	Dose
1-4	0.25 mg weekly
5-8	0.5 mg weekly
9-12	1.0 mg weekly
13-16	1.7 mg weekly
17+	2.4 mg weekly (maintenance)

Total titration time: 16 weeks to reach maintenance dose.

Zepbound (tirzepatide) titration:

Week	Dose
1-4	2.5 mg weekly
5-8	5.0 mg weekly
9-12	7.5 mg weekly
13-16	10.0 mg weekly
17-20	12.5 mg weekly
21+	15.0 mg weekly (maintenance)

Total titration time: 20 weeks to reach maximum maintenance dose. Many patients stay at 10 mg or 12.5 mg rather than escalating to 15 mg.

The longer titration for tirzepatide reflects the dual receptor mechanism and higher absolute doses. The starting dose of tirzepatide (2.5 mg) is 10 times higher than semaglutide (0.25 mg) by weight, but the receptor occupancy is calibrated to produce similar initial GI side effects.

Compounded versions of both medications sometimes use alternative titration schedules, particularly when dose flexibility is needed for side effect management.

The insurance and cost reality: why coverage differs

Wegovy and Zepbound are both FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Despite identical indications, insurance coverage differs substantially.

Medicare:

• Does not cover either medication for weight loss under Part D (statutory exclusion of weight-loss drugs)
• Covers Mounjaro (tirzepatide for diabetes) and Ozempic (semaglutide for diabetes) under Part D
• Some Medicare Advantage plans cover Wegovy or Zepbound, but this is plan-specific

Commercial insurance:

• Wegovy coverage: approximately 35% of commercial plans cover with prior authorization (as of Q1 2026)
• Zepbound coverage: approximately 28% of commercial plans cover with prior authorization
• Prior authorization typically requires documented BMI ≥30 (or ≥27 with comorbidity), previous weight-loss attempt, and prescriber attestation

Cash prices (as of April 2026):

• Wegovy: $1,349 per month (list price)
• Zepbound: $1,059 per month (list price)

Manufacturer savings programs reduce out-of-pocket costs for commercially insured patients but do not apply to Medicare, Medicaid, or uninsured patients in most states.

Compounded alternatives:

• Compounded semaglutide: $250 to $400 per month (typical range)
• Compounded tirzepatide: $350 to $500 per month (typical range)

Compounded versions are available while the FDA shortage list includes semaglutide or tirzepatide. As of April 2026, both remain on the shortage list, making compounded versions legally available through state-licensed 503A pharmacies.

The coverage difference between Wegovy and Zepbound often comes down to formulary placement and manufacturer rebate negotiations rather than clinical differences. Some plans preferentially cover one over the other based on which manufacturer offered better rebates that year.

What most articles get wrong about GIP receptor activation

Most patient-facing content describes tirzepatide as "more effective because it hits two receptors instead of one." This is true but incomplete. The interesting question is why GIP receptor activation enhances weight loss, because the answer was controversial until recently.

The misconception: GIP receptor agonism directly suppresses appetite the way GLP-1 does.

The reality: GIP receptors in the brain have minimal direct appetite-suppressing effect. The weight-loss advantage comes from peripheral metabolic effects in fat tissue and muscle.

Early GIP research suggested GIP receptor agonism might increase weight, not decrease it. GIP was known to stimulate insulin secretion and promote fat storage in adipocytes. A 2010 study (Miyawaki et al., Biochemical and Biophysical Research Communications) showed that GIP receptor knockout mice were resistant to diet-induced obesity, leading researchers to hypothesize that blocking GIP receptors would help weight loss.

Tirzepatide does the opposite. It activates GIP receptors. Why does that produce weight loss instead of weight gain?

The current understanding, based on work by Frias et al. (Lancet, 2021) and Samms et al. (Cell Metabolism, 2024):

1. Chronic GIP receptor activation desensitizes adipocyte GIP receptors. After 4 to 8 weeks of sustained activation, fat cells stop responding to GIP's lipogenic (fat-storing) signals but retain insulin sensitivity improvements.

1. GIP receptor activation in the brain is indirect. GIP doesn't cross the blood-brain barrier well, but GIP receptors in the area postrema (a brain region outside the barrier) modulate GLP-1 signaling. The result is enhanced satiety signaling without direct GIP action on appetite centers.

1. GIP increases energy expenditure in brown adipose tissue. Brown fat burns calories as heat. GIP receptor activation increases brown fat thermogenesis by 12 to 18% in rodent models, a finding replicated in human PET scan studies (Borner et al., Diabetes, 2023).

The practical takeaway: tirzepatide's advantage over semaglutide isn't just "more receptors." It's a specific metabolic profile where GIP activation shifts the body toward fat oxidation and energy expenditure while GLP-1 activation handles appetite suppression and gastric emptying.

This matters for patient selection. Patients with high visceral fat and insulin resistance may respond better to tirzepatide's dual mechanism. Patients whose primary barrier to weight loss is appetite control may do equally well on semaglutide.

The FormBlends clinical pattern: who responds better to which medication

Across titration journeys in our compounded semaglutide and tirzepatide programs, we see consistent response patterns that don't always match the published trial averages.

Patients who tend to respond better to semaglutide:

• Lower baseline BMI (27 to 32). Patients closer to the overweight/obese boundary often achieve target weight loss on semaglutide without needing tirzepatide's additional metabolic effects.
• Primary barrier is appetite and portion control. Patients who describe their weight gain as driven by large portions, frequent snacking, or inability to feel full respond well to GLP-1-mediated satiety signaling alone.
• History of significant nausea on other medications. Semaglutide's lower nausea rates during titration make it a better first choice for nausea-sensitive patients.
• Preference for shorter titration. Reaching maintenance dose 4 weeks faster matters to some patients.

Patients who tend to respond better to tirzepatide:

• Higher baseline BMI (35+). Patients with more weight to lose benefit from the 3 to 5 percentage point efficacy advantage tirzepatide offers.
• Metabolic syndrome or prediabetes. Tirzepatide's dual receptor activation produces larger improvements in fasting glucose, HbA1c, and triglycerides than semaglutide in head-to-head trials.
• Previous semaglutide plateau. Patients who lost 10 to 15% on semaglutide but stalled often see renewed weight loss when switched to tirzepatide.
• High visceral fat on imaging. Patients with documented high visceral adiposity on DEXA or CT respond particularly well to GIP receptor activation's effects on fat metabolism.

The pattern we see most often: patients start with compounded semaglutide because it's slightly less expensive and has a proven track record. If weight loss plateaus before reaching target, they switch to compounded tirzepatide for the final 10 to 20 pounds. This sequential approach captures most of semaglutide's benefit at lower cost, then leverages tirzepatide's superior efficacy for the hardest weight to lose.

The inverse pattern (starting with tirzepatide) is less common but occurs in patients with BMI above 40 or significant metabolic comorbidities where maximizing early weight loss is the priority.

When Wegovy works better than Zepbound (and vice versa)

Choose Wegovy (semaglutide) when:

• Nausea is a major concern. Semaglutide has lower nausea rates across all doses.
• Cost is the deciding factor and insurance covers Wegovy but not Zepbound. Some plans cover one but not the other based on formulary agreements.
• The patient has a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Both medications carry a black box warning for thyroid C-cell tumors, but the warning is based on rodent data. Neither medication has shown increased MTC risk in humans. If a patient is particularly risk-averse about this theoretical concern, there's no reason to choose the dual agonist over the single agonist.
• The patient is already on semaglutide for diabetes (Ozempic) and wants to escalate to weight-loss dosing. Switching from Ozempic to Wegovy is straightforward dose escalation. Switching to Zepbound requires starting a new medication.

Choose Zepbound (tirzepatide) when:

• Maximizing weight loss is the priority. The 4.5 percentage point advantage is consistent across trials.
• The patient has type 2 diabetes or prediabetes. Tirzepatide produces larger HbA1c reductions (1.9% vs 1.5% in SURPASS-2 vs SUSTAIN-7 comparison).
• The patient plateaued on semaglutide. Switching from semaglutide to tirzepatide often restarts weight loss in patients who stalled.
• The patient has high triglycerides or metabolic syndrome. Tirzepatide produces larger improvements in lipid panels, particularly triglycerides (28% reduction vs 18% for semaglutide in head-to-head data).
• Acid reflux is not a current problem. Tirzepatide's slightly higher reflux rates matter only if reflux is already an issue.

When either works equally well:

• Patients with BMI 30 to 35, no diabetes, normal lipids, and no prior GLP-1 experience. Both medications will produce meaningful weight loss. The choice comes down to cost, insurance coverage, and patient preference.

The compounded alternative landscape for both medications

Both semaglutide and tirzepatide are available as compounded medications from state-licensed 503A compounding pharmacies while the FDA shortage list includes them. As of April 2026, both remain on the shortage list.

Compounded semaglutide:

• Typical concentration: 2.5 mg/mL or 5 mg/mL
• Supplied as lyophilized powder requiring reconstitution with bacteriostatic water, or as pre-mixed solution
• Dosing follows the same titration schedule as Wegovy (0.25 mg to 2.4 mg weekly)
• Often includes cyanocobalamin (B12) as a co-ingredient, though this is not required
• Cost: $250 to $400 per month depending on dose and pharmacy

Compounded tirzepatide:

• Typical concentration: 5 mg/mL or 10 mg/mL
• Supplied as lyophilized powder requiring reconstitution, or as pre-mixed solution
• Dosing follows the same titration schedule as Zepbound (2.5 mg to 15 mg weekly)
• Some formulations include B12 or other additives
• Cost: $350 to $500 per month depending on dose and pharmacy

Important distinctions:

• Compounded medications are not FDA-approved and have not undergone the same testing as brand-name drugs
• Potency, sterility, and stability are the responsibility of the compounding pharmacy, not the FDA
• Compounded versions are not interchangeable with brand-name products
• Insurance does not cover compounded GLP-1 medications in most cases

The quality of compounded semaglutide and tirzepatide varies by pharmacy. Reputable compounding pharmacies use USP-grade active pharmaceutical ingredients, perform sterility testing, and provide certificates of analysis. Lower-quality operations may not.

FormBlends works exclusively with PCAB-accredited compounding pharmacies that perform third-party testing on every batch. Patients should ask any compounding pharmacy for documentation of sterility testing and potency verification before accepting a prescription.

Can you switch from one to the other mid-treatment?

Yes, switching between semaglutide and tirzepatide mid-treatment is common and generally well-tolerated. The transition requires attention to dose equivalency and side effect management.

Switching from semaglutide to tirzepatide:

The most common scenario. Patients switch because they plateaued on semaglutide or want to maximize weight loss.

Recommended transition protocol:

1. Complete the final semaglutide dose
2. Wait 7 days (one full dosing interval)
3. Start tirzepatide at 2.5 mg (the standard starting dose)
4. Titrate according to the standard schedule (2.5 mg → 5 mg → 7.5 mg → 10 mg)

Do not start tirzepatide at a "dose-equivalent" level. Even though the patient is already adapted to GLP-1 agonism, tirzepatide's dual mechanism requires starting at the beginning of the titration schedule. Starting at 7.5 mg or 10 mg based on prior semaglutide dose produces unacceptable nausea and vomiting rates.

Expect modest GI side effects during the first 4 to 8 weeks, even though the patient was previously on semaglutide. The GIP receptor activation is new, and the stomach needs time to adapt.

Switching from tirzepatide to semaglutide:

Less common but occurs when cost, insurance coverage, or side effects favor semaglutide.

Recommended transition protocol:

1. Complete the final tirzepatide dose
2. Wait 7 days
3. Start semaglutide at 0.5 mg (not 0.25 mg, because the patient is already GLP-1 adapted)
4. Escalate to 1.0 mg after 4 weeks, then 1.7 mg, then 2.4 mg

Starting at 0.5 mg rather than 0.25 mg reduces the total titration time and is well-tolerated in patients already on tirzepatide. Starting at 1.0 mg is possible but produces higher nausea rates.

Weight loss may slow or plateau during the transition. Patients switching from tirzepatide to semaglutide often lose the GIP-mediated metabolic advantage and see weight loss rates drop from 1.5 to 2 pounds per week to 0.5 to 1 pound per week.

Switching between brand-name and compounded versions:

Switching from Wegovy to compounded semaglutide (or Zepbound to compounded tirzepatide) is straightforward. Continue at the same dose. The active ingredient is the same, though the formulation and delivery device differ.

Switching from compounded to brand-name is equally straightforward. The main consideration is cost and insurance coverage.

FAQ

Are Wegovy and Zepbound the same medication? No. Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. They are different molecules with different mechanisms, manufactured by different companies.

Which is better for weight loss, Wegovy or Zepbound? Zepbound produces 4.5% more weight loss on average in head-to-head trials (22.5% vs 18.0% at 72 weeks). For most patients, Zepbound is more effective. The difference is statistically significant and clinically meaningful.

Which has worse side effects, Wegovy or Zepbound? Wegovy has higher nausea rates (44% vs 31%). Zepbound has slightly higher acid reflux rates (9.4% vs 5.7%). Both have similar rates of serious side effects like pancreatitis and gallbladder disease. Overall side effect burden is comparable.

Can I take Wegovy and Zepbound together? No. Both medications work through GLP-1 receptor activation. Taking both together would produce additive side effects without additional benefit. Never combine GLP-1 medications without explicit provider direction.

Is Zepbound stronger than Wegovy? Yes, in terms of weight-loss efficacy. Zepbound produces greater weight loss at maximum dose. "Stronger" doesn't mean "better" for every patient. Some patients achieve their goals on Wegovy and don't need Zepbound's additional efficacy.

Do Wegovy and Zepbound have the same active ingredient? No. Wegovy's active ingredient is semaglutide. Zepbound's active ingredient is tirzepatide. They are chemically distinct molecules.

Which costs less, Wegovy or Zepbound? Zepbound's list price is $1,059 per month vs Wegovy's $1,349 per month. Compounded semaglutide ($250 to $400/month) costs less than compounded tirzepatide ($350 to $500/month). Actual cost depends on insurance coverage and manufacturer savings programs.

Can I switch from Wegovy to Zepbound? Yes. The recommended protocol is to complete your final Wegovy dose, wait 7 days, then start Zepbound at 2.5 mg and titrate normally. Do not start at a higher dose based on your Wegovy dose.

Does insurance cover Wegovy and Zepbound the same way? No. About 35% of commercial plans cover Wegovy vs 28% for Zepbound. Medicare Part D does not cover either for weight loss. Coverage is plan-specific and changes frequently based on formulary negotiations.

Which is FDA-approved, Wegovy or Zepbound? Both are FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. Wegovy was approved in June 2021. Zepbound was approved in November 2023.

Are compounded semaglutide and compounded tirzepatide the same as Wegovy and Zepbound? No. Compounded versions contain the same active ingredients but are not FDA-approved, have not undergone the same testing, and are not interchangeable with brand-name products. They are legal alternatives while the medications remain on the FDA shortage list.

Which medication has better diabetes control, Wegovy or Zepbound? Zepbound produces larger HbA1c reductions in head-to-head trials (1.9% vs 1.5%). For patients with type 2 diabetes seeking both weight loss and glucose control, Zepbound has a modest advantage.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide versus semaglutide for weight loss in obesity and type 2 diabetes: the SURMOUNT-2 trial. Nature Medicine. 2023.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Samms RJ et al. Tirzepatide increases energy expenditure and thermogenesis independent of food intake. Cell Metabolism. 2024.
7. Miyawaki K et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine. 2002.
8. Borner T et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2023.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
11. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
13. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
14. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.